Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.
about
Plague Vaccine Development: Current Research and Future TrendsChikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the BrainA viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.Multi-Functional Characteristics of the Pseudomonas aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative BacteriaEfficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plagueTNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach.Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plagueThe immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody.Protection against pneumonic plague following oral immunization with a non-replicating vaccine.A chimeric vesiculo/alphavirus is an effective alphavirus vaccineIntranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague.Developing live vaccines against plague.Progress on plague vaccine development.RNA-based viral vectors.Plague vaccines: current developments and future perspectives.Plague Vaccines: Status and Future.Reverse Genetics of Rhabdoviruses
P2860
Q28066875-1E423FA8-B9D0-40FC-8EE7-3628D13EB98EQ28223031-5D8ED2A4-DD91-4F4D-88D3-7F05CC1DEC97Q30370147-1E801E37-00E0-4D1E-B2F7-BA661B7A4CE8Q30431366-CE705EFA-67D0-4514-AAC7-29CE82B161FCQ33635050-5113F607-07B7-4CBC-9FA6-A70349607BD4Q34163944-5C8A89EB-2865-4181-81C7-C30571AD9874Q34380204-9566FDC9-E784-4081-BC04-A7C0C9D65919Q34741896-E1468B3F-B075-4A56-B1A5-70CA3E683629Q35530270-36C23660-41EC-4BC1-8232-EACDD0A4185BQ35867988-230F796D-1070-428E-87D0-8E7C411C2CBCQ36007614-DABBA2D9-A76E-4BFE-9C35-C02D621D5E24Q36099515-E12CD9FD-75F9-46C1-94CF-AADE1E2E3285Q36506753-1BFCF63A-4AF6-4F3C-BF29-9BA63FC46B64Q36911486-88F7D880-FC78-4057-981E-427759AF49EBQ37355852-9C095FCA-BB60-49AA-9600-F892575EF48CQ37599376-BBD9DFF7-DEB6-45DA-BDB7-D25823EC5E59Q37889155-520FBDB1-304D-467A-B202-438A6C04F968Q38266413-58CAEC41-31CA-4C1B-B620-C03050DD28D4Q38514208-2A3F97A2-CFE4-4586-B2E2-B48C9832B855Q38813137-385DA544-8304-4822-AAE2-8AEECAF0B469Q57077874-4D73C328-76DB-48C6-BD16-75E2DE474123
P2860
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Single-dose, virus-vectored va ...... llenge for optimal protection.
@en
Single-dose, virus-vectored va ...... llenge for optimal protection.
@nl
type
label
Single-dose, virus-vectored va ...... llenge for optimal protection.
@en
Single-dose, virus-vectored va ...... llenge for optimal protection.
@nl
prefLabel
Single-dose, virus-vectored va ...... llenge for optimal protection.
@en
Single-dose, virus-vectored va ...... llenge for optimal protection.
@nl
P2093
P2860
P1433
P1476
Single-dose, virus-vectored va ...... llenge for optimal protection.
@en
P2093
Anasuya Chattopadhyay
David S Perlin
Guillaume Delmas
John K Rose
Rema Suresh
Steven Park
Svetlana Senina
P2860
P304
P356
10.1016/J.VACCINE.2008.09.031
P407
P577
2008-10-01T00:00:00Z